A major pharmaceutical fraud investigation is underway in Bengaluru after authorities discovered that counterfeit cancer medications were being supplied to more than 90 hospitals across the city at discounts as high as 50 per cent. The Karnataka drug control department initiated the probe after a routine quality check uncovered multiple batches of anti-cancer drugs that failed standard authenticity tests.
According to sources close to the investigation, several pharmaceutical suppliers were found selling these substandard medicines at significantly lower prices compared to market rates — a pricing strategy that initially raised suspicions among procurement officials at a few hospitals. When samples from these suppliers were sent for rigorous testing, the results confirmed the presence of counterfeit active ingredients in multiple life-saving oncology drugs.
The hospitals currently under scrutiny include both private institutions and smaller nursing homes scattered across Bengaluru's urban and suburban areas. Authorities have issued show-cause notices to the suppliers involved and sealed records at their warehouses. Several hospital pharmacy heads have been asked to provide purchase records and supplier documentation for the affected drug batches.
Drug enforcement officials stated that the fake medications included commonly prescribed cancer treatments such as chemotherapy agents and targeted therapy drugs. These are critical medications where even minor variations in composition can have severe consequences for patients undergoing prolonged treatment.
The Karnataka government has directed its Drug Control Department to conduct surprise inspections across all 90-plus hospitals identified in the probe. A senior official said strict action would be taken against any hospital found to have stocked or administered the counterfeit drugs to patients. Legal proceedings under the Drugs and Cosmetics Act are expected to follow.
This incident has reignited debates about supply chain transparency in India's pharmaceutical distribution network. Bengaluru, often called India's healthcare hub, relies on a complex web of distributors and wholesalers, making it challenging to trace the origin of adulterated products. Patients and advocacy groups have expressed alarm, urging the state to strengthen monitoring mechanisms for critical life-saving drugs.
